270 related articles for article (PubMed ID: 33352838)
1. Preclinical Evaluation of the Copper-64 Labeled GRPR-Antagonist RM26 in Comparison with the Cobalt-55 Labeled Counterpart for PET-Imaging of Prostate Cancer.
Baun C; Mitran B; Rinne SS; Dam JH; Olsen BB; Tolmachev V; Orlova A; Thisgaard H
Molecules; 2020 Dec; 25(24):. PubMed ID: 33352838
[TBL] [Abstract][Full Text] [Related]
2. High Contrast PET Imaging of GRPR Expression in Prostate Cancer Using Cobalt-Labeled Bombesin Antagonist RM26.
Mitran B; Thisgaard H; Rosenström U; Dam JH; Larhed M; Tolmachev V; Orlova A
Contrast Media Mol Imaging; 2017; 2017():6873684. PubMed ID: 29097932
[TBL] [Abstract][Full Text] [Related]
3.
Rinne SS; Abouzayed A; Gagnon K; Tolmachev V; Orlova A
Sci Rep; 2021 Feb; 11(1):3631. PubMed ID: 33574368
[TBL] [Abstract][Full Text] [Related]
4. Selection of optimal chelator improves the contrast of GRPR imaging using bombesin analogue RM26.
Mitran B; Varasteh Z; Selvaraju RK; Lindeberg G; Sörensen J; Larhed M; Tolmachev V; Rosenström U; Orlova A
Int J Oncol; 2016 May; 48(5):2124-34. PubMed ID: 26983776
[TBL] [Abstract][Full Text] [Related]
5. Trastuzumab cotreatment improves survival of mice with PC-3 prostate cancer xenografts treated with the GRPR antagonist
Mitran B; Rinne SS; Konijnenberg MW; Maina T; Nock BA; Altai M; Vorobyeva A; Larhed M; Tolmachev V; de Jong M; Rosenström U; Orlova A
Int J Cancer; 2019 Dec; 145(12):3347-3358. PubMed ID: 31077356
[TBL] [Abstract][Full Text] [Related]
6. The effect of macrocyclic chelators on the targeting properties of the 68Ga-labeled gastrin releasing peptide receptor antagonist PEG2-RM26.
Varasteh Z; Mitran B; Rosenström U; Velikyan I; Rosestedt M; Lindeberg G; Sörensen J; Larhed M; Tolmachev V; Orlova A
Nucl Med Biol; 2015 May; 42(5):446-454. PubMed ID: 25684649
[TBL] [Abstract][Full Text] [Related]
7. Two Novel [
Kanellopoulos P; Bezverkhniaia E; Abouzayed A; Rosenström U; Tolmachev V; Orlova A
ACS Omega; 2024 Apr; 9(16):18608-18616. PubMed ID: 38680331
[TBL] [Abstract][Full Text] [Related]
8. In vitro and in vivo evaluation of a (18)F-labeled high affinity NOTA conjugated bombesin antagonist as a PET ligand for GRPR-targeted tumor imaging.
Varasteh Z; Aberg O; Velikyan I; Lindeberg G; Sörensen J; Larhed M; Antoni G; Sandström M; Tolmachev V; Orlova A
PLoS One; 2013; 8(12):e81932. PubMed ID: 24312607
[TBL] [Abstract][Full Text] [Related]
9. Selection of an optimal macrocyclic chelator improves the imaging of prostate cancer using cobalt-labeled GRPR antagonist RM26.
Mitran B; Thisgaard H; Rinne S; Dam JH; Azami F; Tolmachev V; Orlova A; Rosenström U
Sci Rep; 2019 Nov; 9(1):17086. PubMed ID: 31745219
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of a novel GRPR antagonist for prostate cancer PET imaging: [
Mansour N; Paquette M; Ait-Mohand S; Dumulon-Perreault V; Guérin B
Nucl Med Biol; 2018 Jan; 56():31-38. PubMed ID: 29154145
[TBL] [Abstract][Full Text] [Related]
11. Positron Emission Tomography Imaging of Prostate Cancer with Ga-68-Labeled Gastrin-Releasing Peptide Receptor Agonist BBN
Cheng S; Lang L; Wang Z; Jacobson O; Yung B; Zhu G; Gu D; Ma Y; Zhu X; Niu G; Chen X
Bioconjug Chem; 2018 Feb; 29(2):410-419. PubMed ID: 29254329
[TBL] [Abstract][Full Text] [Related]
12. Synthesis and characterization of a high-affinity NOTA-conjugated bombesin antagonist for GRPR-targeted tumor imaging.
Varasteh Z; Velikyan I; Lindeberg G; Sörensen J; Larhed M; Sandström M; Selvaraju RK; Malmberg J; Tolmachev V; Orlova A
Bioconjug Chem; 2013 Jul; 24(7):1144-53. PubMed ID: 23763444
[TBL] [Abstract][Full Text] [Related]
13. Impact of dianionic and dicationic linkers on tumor uptake and biodistribution of [
Mansour N; Dumulon-Perreault V; Ait-Mohand S; Paquette M; Lecomte R; Guérin B
J Labelled Comp Radiopharm; 2017 Apr; 60(4):200-212. PubMed ID: 28129446
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and biological evaluation of copper-64 radiolabeled [DUPA-6-Ahx-(NODAGA)-5-Ava-BBN(7-14)NH2], a novel bivalent targeting vector having affinity for two distinct biomarkers (GRPr/PSMA) of prostate cancer.
Bandari RP; Jiang Z; Reynolds TS; Bernskoetter NE; Szczodroski AF; Bassuner KJ; Kirkpatrick DL; Rold TL; Sieckman GL; Hoffman TJ; Connors JP; Smith CJ
Nucl Med Biol; 2014 Apr; 41(4):355-63. PubMed ID: 24508213
[TBL] [Abstract][Full Text] [Related]
15. Small-animal PET of tumors with (64)Cu-labeled RGD-bombesin heterodimer.
Liu Z; Li ZB; Cao Q; Liu S; Wang F; Chen X
J Nucl Med; 2009 Jul; 50(7):1168-77. PubMed ID: 19525469
[TBL] [Abstract][Full Text] [Related]
16. Preclinical Characterization of a Stabilized Gastrin-Releasing Peptide Receptor Antagonist for Targeted Cancer Theranostics.
Abouzayed A; Kanellopoulos P; Gorislav A; Tolmachev V; Maina T; Nock BA; Orlova A
Biomolecules; 2023 Jul; 13(7):. PubMed ID: 37509170
[TBL] [Abstract][Full Text] [Related]
17. N-terminal modifications improve the receptor affinity and pharmacokinetics of radiolabeled peptidic gastrin-releasing peptide receptor antagonists: examples of 68Ga- and 64Cu-labeled peptides for PET imaging.
Gourni E; Mansi R; Jamous M; Waser B; Smerling C; Burian A; Buchegger F; Reubi JC; Maecke HR
J Nucl Med; 2014 Oct; 55(10):1719-25. PubMed ID: 25146125
[TBL] [Abstract][Full Text] [Related]
18. Preclinical Evaluation of
Abouzayed A; Rinne SS; Sabahnoo H; Sörensen J; Chernov V; Tolmachev V; Orlova A
Pharmaceutics; 2021 Jan; 13(2):. PubMed ID: 33573232
[TBL] [Abstract][Full Text] [Related]
19. Synthesis, radiolabeling, and evaluation of gastrin releasing peptide receptor antagonist
Satpati D; Vats K; Sharma R; Kameswaran M; Sarma HD; Dash A
J Labelled Comp Radiopharm; 2019 Oct; 62(12):843-849. PubMed ID: 31378967
[TBL] [Abstract][Full Text] [Related]
20. The effect of mini-PEG-based spacer length on binding and pharmacokinetic properties of a 68Ga-labeled NOTA-conjugated antagonistic analog of bombesin.
Varasteh Z; Rosenström U; Velikyan I; Mitran B; Altai M; Honarvar H; Rosestedt M; Lindeberg G; Sörensen J; Larhed M; Tolmachev V; Orlova A
Molecules; 2014 Jul; 19(7):10455-72. PubMed ID: 25036155
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
